Canaccord Genuity set a $85.00 price objective on Radius Health Inc. (NASDAQ:RDUS) in a report issued on Monday morning. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Several other equities analysts have also recently weighed in on RDUS. Zacks Investment Research raised Radius Health from a sell rating to a hold rating in a research note on Tuesday, July 5th. Jefferies Group reaffirmed a hold rating on shares of Radius Health in a research note on Friday, August 5th. HC Wainwright began coverage on Radius Health in a research note on Monday, May 23rd. They set a buy rating and a $55.00 target price on the stock. JPMorgan Chase & Co. reiterated a buy rating and set a $70.00 price target on shares of Radius Health in a report on Friday, August 5th. Finally, Cowen and Company reiterated a buy rating on shares of Radius Health in a report on Thursday, August 4th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $61.73.

Shares of Radius Health (NASDAQ:RDUS) opened at 55.92 on Monday. Radius Health has a 52-week low of $24.75 and a 52-week high of $77.10. The firm’s market cap is $2.41 billion. The stock’s 50 day moving average is $54.45 and its 200-day moving average is $40.78.

Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by $0.06. During the same quarter in the prior year, the firm earned ($0.61) earnings per share. Equities analysts anticipate that Radius Health will post ($3.95) earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of RDUS. Geode Capital Management LLC raised its stake in Radius Health by 5.3% in the first quarter. Geode Capital Management LLC now owns 235,675 shares of the biopharmaceutical company’s stock valued at $7,409,000 after buying an additional 11,852 shares during the period. State Street Corp raised its position in shares of Radius Health by 39.9% in the first quarter. State Street Corp now owns 1,588,379 shares of the biopharmaceutical company’s stock worth $49,938,000 after buying an additional 453,302 shares during the period. Wexford Capital LP acquired a new position in shares of Radius Health during the first quarter worth approximately $959,000. ING Groep NV raised its position in shares of Radius Health by 159.2% in the first quarter. ING Groep NV now owns 451,486 shares of the biopharmaceutical company’s stock worth $14,181,000 after buying an additional 277,311 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of Radius Health by 79.7% in the first quarter. JPMorgan Chase & Co. now owns 147,112 shares of the biopharmaceutical company’s stock worth $4,626,000 after buying an additional 65,259 shares during the period. Hedge funds and other institutional investors own 99.91% of the company’s stock.

About Radius Health

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

5 Day Chart for NASDAQ:RDUS

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.